Express Courier treats obesity, diabetes and other diseases, 236 million US dollars to help develop innovative therapies for the gut-brain axis

▎WuXi AppTec Content Team Editor On February 15, 2022, Kallyope announced the completion of a $236 million Series D financing
.

The funds will be used to advance the company's "gut-brain axis" groundbreaking drug discovery platform, clinical trials and multiple pipeline programs spanning a broad range of therapeutic areas
.

Kallyope has built a highly integrated cutting-edge technology platform that integrates several complex technologies, including single-cell sequencing, optogenetics and chemogenetics, organoids, and more, to discover transformative small molecules acting on the gut-brain axis therapeutic drugs
.

The gut-brain axis can be interpreted as a two-way signal communication network between the gut and the brain.
The development of gut-brain biology has shown that these organs communicate information through hormones and neural circuits, regulating and controlling many important physiological and behavioral functions.
aspect
.

Because of this central biological role of the gut-brain axis, many diseases are associated with its associated deficits, including obesity, diabetes, inflammatory diseases, depression, and Parkinson's disease
.

By uncovering the connections between the gut and the brain, the Kallyope platform has been used to generate novel therapeutic options across several related therapeutic areas, including metabolism, immunology and inflammation, and central nervous system diseases
.

A key element of its strategy is targeting targets relevant to gut and gut-brain physiology with gut-restricted molecules, a novel approach that promises to increase the speed and chance of success in drug discovery and development
.

In the past 13 months, Kallyope has advanced four compounds into the clinic in two of its lead programs for the treatment of type 2 diabetes, obesity and gastrointestinal barrier diseases
.

With this new funding, Kallyope will continue to move forward with these trials, as well as accelerate the progress of more than 20 programs and molecules in its pipeline, and further develop its platform
.

▲Kallyope R&D pipeline (Image source: Kallyope's official website) "Since our establishment 6 years ago, Kallyope has pioneered the study of the gut-brain axis and has rapidly and ingeniously developed a transformative drug discovery platform
.

" President of Kallyope Mr.
Jay Galeota, Chief Executive Officer, said, "We are delighted to have the backing of a distinguished group of investors who represent strong confidence in our science and team
.

" Reference: [1] Kallyope Raises $236M Series D Financing to Fuel Expansion of Novel Gut-Brain Axis Therapeutic Programs.
Rretrieved February 2022, from https://kallyope.
com/kallyope-raises-236m-series-d-financing-to-fuel-expansion-of-novel-gut-brain- axis-therapeutic-programs/Disclaimer: The WuXi AppTec content team focuses on introducing global biomedical health research progress
.

This article is for information exchange purposes only, and the views expressed in this article do not represent WuXi AppTec's position, nor do they represent WuXi AppTec's support or opposition to the views expressed in this article
.

This article is also not a treatment plan recommendation
.

For guidance on treatment options, please visit a regular hospital
.